Self-administered health tests widely available in UK pharmacies and supermarkets may be delivering misleading or unreliable results, prompting researchers and medical experts to call for stricter regulation and greater transparency in the industry.
Two newly published studies in the British Medical Journal (BMJ) have raised concerns over the effectiveness and safety of many over-the-counter test kits marketed to consumers for conditions ranging from bowel cancer and menopause to thyroid disorders and vitamin deficiencies.
A team of researchers from the University of Birmingham analysed 30 such self-testing kits purchased in 2023, costing between £1.89 and £39.99.
They found that only 14 included any claim regarding their accuracy, while fewer than one in four offered clear follow-up guidance based on test results. Nearly half of the kits advised users to seek medical advice regardless of the outcome—potentially adding pressure on already strained NHS services.
“Self-tests can offer public health benefits, but they must be accurate, easy to use, and come with clear instructions,” said Prof. Jon Deeks, who led the research. “Current regulations are not doing enough to protect consumers.”
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has acknowledged the concerns and says it is undertaking a major review of safety standards for such devices.
Joseph Burt, Head of Diagnostics at MHRA, said the regulator is considering introducing new rules requiring manufacturers to publish summaries of clinical performance data.
“We urge the public to look for CE or UKCA markings and follow instructions closely,” said Burt. “If in doubt, always consult a healthcare professional.”
The BMJ editorial warned that the rapid growth of the direct-to-consumer testing market—expected to generate £660 million annually by 2030—could worsen health inequalities, especially if tests are promoted based on affordability rather than clinical need.
Dr. Bernie Croal, President of the Royal College of Pathologists, also raised alarms about the risks of low-quality testing. “False reassurance and unnecessary follow-ups both present serious consequences for patients and the NHS,” he said.
Although many of the test kits claimed accuracy rates above 98%, the studies found little publicly available evidence to support such claims. Researchers classified 60% of the tests as posing a high risk to users due to the lack of regulatory oversight and transparency.
The Royal College of General Practitioners has echoed calls for clearer standards and greater openness within the self-testing industry, emphasizing the need for consumer protection as the market expands.
ALSO READ : Till Operator Vanishes with US$12,000 from N. Richards
For comments, Feedback and Opinions do get in touch with our editor on WhatsApp: +44 7949 297606 or Email: editor@thezimbabwetimes.co.zw.
